Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE:JNJ) reported Phase 1b/2 OrigAMI-4 results showing first-line subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus pembrolizumab produced a 56% confirmed overall response rate (22/39) and a 10% complete response rate in PD-L1-positive, HPV-unrelated recurrent or metastatic HNSCC.
Median follow-up was 10.4 months; median PFS was 7.7 months and median OS was not estimable. Safety matched known profiles with no new signals.
Johnson & Johnson (NYSE: JNJ) announced a more than $1 billion investment in a next‑generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The site is expected to create >4,000 construction jobs and >500 biomanufacturing jobs and is part of a $55 billion U.S. investment through early 2029.
This expands JNJ’s Pennsylvania footprint, supporting its roughly $10 billion annual economic impact and adding to ten statewide facilities totaling more than 2 million square feet.
Johnson & Johnson (NYSE: JNJ) announced that the U.S. FDA granted Breakthrough Therapy Designation on Feb 18, 2026 for subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as monotherapy for adults with recurrent or metastatic, HPV-unrelated head and neck squamous cell carcinoma after platinum and PD-1/PD-L1 therapy.
The designation is based on Phase 1b/2 OrigAMI-4 data showing rapid, durable responses in a heavily pretreated population; a Phase 3 OrigAMI-5 trial is ongoing.
Johnson & Johnson (NYSE: JNJ) announced FDA approval of a new monthly dosing schedule for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combined with oral LAZCLUZE for first-line EGFR-mutated advanced NSCLC, available as early as Week 5.
The approval preserves established efficacy and safety versus the bi-weekly subcutaneous schedule, shows pharmacokinetic comparability to prior IV and SC regimens, and reports a fivefold reduction in administration-related reactions versus historical IV delivery.
Summary not available.
Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026, with management in a Fireside Chat at 11:30 a.m. ET. A live audio webcast and an archived replay (available ~48 hours later) will be on the company's investor website.
Johnson & Johnson (NYSE: JNJ) presented 12-month pilot-phase OMNY-AF results showing 90% freedom from atrial fibrillation and 100% acute procedural success across a 30-patient cohort, with no procedure-related adverse events and 56.7% of cases using zero fluoroscopy.
Presentations also highlighted VARIPULSE platform safety: a 0.22% neurovascular event rate in 6,811 patients after workflow and irrigation optimizations, and high same-day discharge rates.
Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026.
Management will take part in a Fireside Chat at 11:10 a.m. ET. A live audio webcast will be available on the company’s Investor Relations website, with an archived replay posted approximately 48 hours after the event.
Johnson & Johnson (NYSE:JNJ) announced FDA approval (Jan 27, 2026) of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) combined with bortezomib, lenalidomide and dexamethasone (D-VRd) for adult newly diagnosed multiple myeloma patients who are transplant ineligible.
CEPHEUS Phase 3 results: overall MRD-negativity 52.3% vs 34.8% (sensitivity 10-5) at 22 months; sustained MRD≥12 months 42.6% vs 25.3% at 39 months; progression or death reduced 40% (HR 0.60; 95% CI 0.41–0.88). At ~59 months, complete response or better was 81.2% vs 61.6%. Overall survival data not yet mature.
Johnson & Johnson (NYSE: JNJ) announced it has donated $100 million of MedTech products since 2020 and plans an additional $20 million in 2026 to support programs and impact investments that expand access to cardiovascular, surgical and vision care. These commitments operate under J&J CareCommunity and involve partners including Lions Clubs International Foundation, Operation Smile, American Heart Association and Global Surgery Foundation. The effort reaches over 300,000 healthcare professionals annually and includes a $1 million commitment to SURGfund and long‑running programs such as Sight For Kids, which has reached > 55 million students.